IRVINE, Calif.--(BUSINESS WIRE)--My Vape Order, Inc. (MVO), a trusted provider of nicotine e-liquid products marketed under the AIR FACTORY® brand, has announced that on October 9, 2020, the U.S. Food and Drug Administration (FDA) issued a Filing Letter notifying MVO that the AIR FACTORY® Premarket Tobacco Application (PMTA) met FDA’s PMTA filing requirements and was moving forward into FDA’s substantive scientific review phase.
MVO’s CEO, Kyle Godfrey, commented, “[i]n this critical phase, FDA will review the extensive scientific data and research submitted with the AIR FACTORY® PMTA to determine whether the AIR FACTORY® products consumers know and love are 'appropriate for the protection of public health' - the standard that FDA considers when deciding which products to allow for sale. The AIR FACTORY® PMTA was the culmination of years of planning and extensive toxicological testing and scientific research. We look forward to working with FDA on its review of the AIR FACTORY® products, with the ultimate goal of obtaining FDA marketing orders for the products.” Godfrey noted that the company would continue to provide updates regarding FDA’s PMTA review of the AIR FACTORY® products.
